thats what I feel, market expectation is now focus on the 25% additional market integration and cross selling instead of ARR. ARR is now second figure to consider at the moment
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%